• Western blot analysis of IGFALS Antibody. The lane on the right is blocked with the IGFALS peptide.
  • Western blot analysis of the lysates from RAW264.7cells using IGFALS antibody.
  • Western blot analysis of CoLo cells using ALS Polyclonal Antibody

Anti-IGFALS antibody (303-352 aa) (STJ91566)

SKU:
STJ91566

Current Stock:
Host: Rabbit
Applications: WB/ELISA
Reactivity: Human/Rat/Mouse
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Insulin-like growth factor-binding protein complex acid labile subunit (303-352 aa) is suitable for use in Western Blot and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-1:2000
ELISA 1:10000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: IGFALS
Gene ID: 3483
Uniprot ID: ALS_HUMAN
Immunogen Region: 303-352 aa
Specificity: ALS Polyclonal Antibody detects endogenous levels of ALS protein.
Immunogen: The antiserum was produced against synthesized peptide derived from the human IGFALS at the amino acid range 303-352
Function Involved in protein-protein interactions that result in protein complexes, receptor-ligand binding or cell adhesion.
Protein Name Insulin-Like Growth Factor-Binding Protein Complex Acid Labile Subunit
Als
Database Links Reactome: R-HSA-381426
Cellular Localisation Secreted
Extracellular Space
Alternative Antibody Names Anti-Insulin-Like Growth Factor-Binding Protein Complex Acid Labile Subunit antibody
Anti-Als antibody
Anti-IGFALS antibody
Anti-ALS antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance